Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality

Abstract EN

Purpose.

To evaluate the therapeutic efficacy of subretinal BSS injections done during vitrectomy for refractory diabetic macular edema (DME) resistant to other modes of treatment including previous vitrectomy.

Materials and Methods.

A prospective, interventional noncomparative case series in which cases had refractory DME with a central macular thickness (CMT) ≥ 300 μm, despite previous anti-VEGF therapy (ranibizumab or bevacizumab with shifting to aflibercept).

Some cases even received intravitreal triamcinolone acetonide injection, before attempting this solution.

The study included group 1, surgically naïve eyes, and group 2, cases with persistent edema despite a previous vitrectomy (7 eyes (25%)).

The cases were also divided into group a, eyes with normal vitreomacular interface, and group b, with abnormal vitreomacular attachment (VMA) (6 (21.4%)).

The 1ry endpoint for this study was the change in CMT after 9–12 months from surgery.

The 2ry endpoints were change in BCVA, recurrence of DME, and surgical complications.

Results.

The study included 28 eyes, 6 (21.4%) of which suffered from edema recurrence.

The mean recorded CMT was 496 ± 88.7 μm and 274.1 ± 31.6 μm preoperatively and postoperatively, respectively.

In all eyes, the preoperative mean BCVA in decimal form was 0.2 ± 0.11, which improved significantly to 0.45 ± 0.2.

In the end, the CMT of groups 1 and 2 measured 239 μm and 170.8 μm, respectively (p=0.019).

The preoperative BCVA in groups 1 and 2 was 0.16 ± 0.07 and 0.37 ± 0.14, respectively, which improved to a mean of 0.34 ± 0.09 and 0.7 ± 0.16 postoperatively, respectively (p=0.185).

Conclusion.

Vitrectomy with a planned foveal detachment technique was shown to be a promising solution for refractory DME cases with rapid edema resolution.

CMT was shown to improve more in eyes where conventional vitrectomy was not attempted.

Moreover, cases with VMA resistant to pharmacotherapy was shown to respond well to this technique.

The study has been registered in Contact ClinicalTrials.gov PRS Identifier: NCT03345056.